Steadfast Dependability. Local Capacity.
Curia is your trusted CDMO, providing best-in-class expertise across drug substance and drug product manufacturing for biologics and small molecules. As the dependable partner for pharma and biotech, we offer over 30 years of experience and an integrated network of sites around the world, along with local regulatory know-how. From discovery through manufacturing, from launch to commercialization, we leverage state-of-the-art technology, scientific and process experts, and proven capabilities to expedite your molecule’s journey to patients, even amidst shifting market conditions.
Contact us to find out how.
With Curia, you are assured immediate capacity, operational excellence and shortened timelines to advance your program from curiosity to cure.
Expanded Capacity
To meet increased industry demand for onshore sterile fill finish capabilities amidst industry consolidation and supply constraints, Curia is expanding our pre-filled syringe (PFS) manufacturing capacity in our New Mexico facility.
The facility has recently launched its first commercially approved product on the Syntegon® PFS line and still has available capacity. In addition, Curia has invested in a Bausch+Ströbel® VarioSysTM flexline with a SKAN® isolator, bringing on significant additional capacity for both vial and/or PFS/cartridge manufacturing. The new manufacturing line will be qualified in Q4 2024 to support increased market needs.
Benefits of Sourcing APIs from Local CDMO
The COVID-19 pandemic brought the global interdependency of pharmaceutical supply chains into sharp focus, revealing vulnerabilities and reigniting discussions around the value of reshoring production. Reshoring drug production is a current strategy, with domestic production now heavily incentivized by U.S. government programs. Watch this video as our experts in Rensselaer, NY discuss the benefits of sourcing APIs from a local CDMO.
